Update on Clostridium difficile Infection

Slides:



Advertisements
Similar presentations
Relapsing and Severe C. difficile Disease Role of Fecal Microbiota Transfer.
Advertisements

Antibiotic Stewardship Curriculum Developed by: Vera P. Luther, M.D.
Deadly Diarrhea …and the salvation of stool Teri Brentnall, M.D. Professor, Medicine Gastroenterology.
C. Difficile and Fecal Microbiota Therapy
2013 CLOSTRIDIUM DIFFICILE EDUCATIONAL AND CONSENSUS CONFERENCE March 11-12, 2013.
Management of Clostridium difficile Infections
Leav, B. A., et al.(2010) “Serum Anti-toxin B Antibody Correlates with Protection from Recurrent Clostridium Difficile Infection (CDI)”. Vaccine 28:
Fecal Microbiota Transplant
Clostridium difficile Prevention and Treatment Katrina Beining & Christina Gardner Introduction Clostridium difficile (C. diff) is a gram-positive, spore-forming.
Preventing and Treating C.difficile Lisa Casey, M.D. Assistant Professor, UT Southwestern Medical Center TSGE / SGNA Annual Scientific Meeting September.
Effect of prolonging Clostridium difficile (CD) treatment on recurrence rate in patients receiving concomitant systemic antibiotic therapy 5-yr retrospective.
Treatment duration and outcomes for male urinary tract infection (UTI) Retrospective review of 33,336 patients with index UTI from Veterans Affairs database.
R3 민준기 Pf. 이창균. Introduction 1978 – Clostridium difficile major cause of diarrhea – Pseudomembranous colitis associated with the use of antimicrobial.
© 2013 Pearson Education, Inc. Bell Ringer  What is an endospore, and what special characteristics do endospore forming bacteria have?
JAMA Internal Medicine May 2015 Volume 175, Number5 R1 조한샘 / Prof. 이창균.
Clostridium difficile infection (CDI) in the ICU and Clostridium difficile outcomes in the PROSPECT Main Trial Erick Duan MD FRCPC Presented at the CCCTG.
Janet T. Lee, MD, Rosemary F. Kelly, MD, Marshall I
Clostridium difficile Infection Biology & Public Health Impact
From: Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile InfectionA Randomized Trial Ann Intern Med.
From: Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile InfectionA Randomized Trial Ann Intern Med.
HCF (not BMC) Associated Association Indeterminate
YOUR ACTIONS PROTECT ANTIBIOTICS, RALLY TOGETHER AT
Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection  F. Cao, C.X. Chen, M. Wang,
Antimicrobial Therapy (Vancomycin and/or Metronidazole)
New Guidelines to Prevent SCD: What You Need to Know
NOACs for Cancer-Associated Thrombosis:
Risk Stratification in PAH: What Do the Latest Data Suggest?
HCV: Who Should We Screen and Why?
Infection Prevention: A Hierarchy of Controls Approach
Volume 149, Issue 1, Pages (July 2015)
Raseen Tariq, MBBS, Renee M. Weatherly, Patricia P
The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection  Jessica R. Allegretti, MD, MPH, Zain.
Updates in Hodgkin Lymphoma
J.-C. Lagier  Clinical Microbiology and Infection 
Scientific Method Lesson One.
Transient Flare of Ulcerative Colitis After Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection  Lauren M. De Leon, James B.
RSV Bronchiolitis.
The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection  R. Singh, M. Nieuwdorp, I.J.M.
HCV Screening.
Evaluation of the Patient With HCV Infection
Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis  J.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics  Y.H. van Beurden, S. Nezami,
A Case-based Approach to RSV Disease
David L. McCollum, J. Martin Rodriguez 
Probiotics in the Prevention of C Difficile Infection
Hospital Acquired Infections
Treatment Update on Clostridium difficile Infection
Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.
Program Goals Overview Is NEDA a Reasonable Target?
CMV in the HSCT Recipient
New Strategies to Reduce HF Readmissions
Are Proton Pump Inhibitors Affecting Intestinal Microbiota Health?
C. difficile Update Kim Vermedal, RN, MSN, CIC APIC January 25, 2019.
Manipulating the Microbiota
Volume 149, Issue 1, Pages (July 2015)
Improving Adherence to Antiplatelet Therapy After an ACS Event
The economic burden of Clostridium difficile
Disease Burden of VTE Phases of VTE Treatment.
Prioritizing Prevention of HPV-Related Disease
Selecting Treatment Approaches in Hemophilia
R. U. Varier, E. Biltaji, K. J. Smith, M. S. Roberts, M. K. Jensen, J
Increasing numbers of hospitalizations and deaths with mention of Clostridium difficile infection, north-eastern Italy, 2008–2013  U. Fedeli, E. Schievano,
Microbiologic factors affecting Clostridium difficile recurrence
At the Crossroads of Coagulation
C.P. Kelly  Clinical Microbiology and Infection 
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Volume 156, Issue 5, Pages e3 (April 2019)
Our Community Where is …?.
First implementation of frozen, capsulized faecal microbiota transplantation for recurrent Clostridium difficile infection into clinical practice in Europe 
Presentation transcript:

Update on Clostridium difficile Infection

CDI-Related Mortality

Not Just a Hospital Infection

BI/NAP1/027 Virulent CDI

What is C difficile?

Gut Microbiota An Eco-community of Bacteria

Risk Factors for C difficile Infection

Defining C difficile Disease

Stages of C difficile Infection

Testing for C difficile

ACG Guidelines Testing

Preventing Spread of C difficile in the Hospital

ACG Treatment Guidelines First Episode

ACG Treatment Guidelines Recurrent Disease

Fecal Microbiota Transplantation

Transplantation Procedure

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.